Survival Benefit of Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Abstract Introduction: Atezolizumab plus bevacizumab (Atezo/Bev) improves overall survival (OS) and progression-free survival (PFS) in hepatocellular carcinoma (HCC). Whether adding on-demand transcatheter arterial chemoembolization (TACE) to Atezo/Bev (ABC-TACE) adds benefit, and whether this depends on the tumor response already achieved, remains unclear. Methods: We retrospectively analyzed 567 patients with unresectable HCC given Atezo/Bev at 16 Japanese institutions. Those who underwent on-demand TACE during Atezo/Bev treatment formed the ABC-TACE group (n = 90) and those who did not the Atezo/Bev-alone control group (n = 477). Because TACE was performed at a variable time (median 199 days after initiation), the primary analysis entered TACE as a time-dependent covariate, with landmark analyses at 3, 6, and 9 months. An exploratory analysis stratified the cohort by the response documented before TACE: partial response (PR), stable disease (SD) with or without shrinkage, and progressive disease (PD). Adverse events were graded by CTCAE v5.0, and the albumin-bilirubin (ALBI) score was compared by mixed-effects modeling. Results: Adjusted for ten prespecified covariates, TACE was associated with longer OS (hazard ratio [HR] = 0.48, 95% confidence interval [CI]: 0.32–0.71; p < 0.001) and PFS (HR = 0.62, 95% CI: 0.42–0.92; p = 0.018). Assigning exposure at any time, which ignores immortal time, gave HRs of 0.37 and 0.34. Landmark analyses were concordant in direction. Grade ≥3 adverse events (27.8% versus 35.2%; p = 0.184) and ALBI trajectories (ever- vs never-TACE; p = 0.198) did not differ significantly. Stratified by pre-TACE response (exploratory), OS HRs were 0.12 for PR, 0.42 and 0.53 for the two SD strata, and 1.51 for PD (interaction p = 0.020). The estimates are imprecise (only 2 deaths in the PR stratum followed embolization), the interaction did not persist when the PD stratum was excluded (p = 0.097), and PFS showed no corresponding interaction (p = 0.589). Conclusion: In this real-world cohort, ABC-TACE was associated with longer survival than Atezo/Bev alone. The response-stratified analyses are exploratory and do not establish effect modification. These findings are hypothesis-generating rather than practice-changing, and prospective response-stratified evaluation is required before a response-guided approach can be adopted.
Authors
- Hiroshi Numao (ORCID: https://orcid.org/0000-0002-6476-7038)
- Tamami Abe (ORCID: https://orcid.org/0000-0001-8314-7187)
- Nobukazu Tanabe
- Wataru Sato (ORCID: https://orcid.org/0009-0006-4188-5871)
- Kazumichi Abe (ORCID: https://orcid.org/0000-0001-5359-9465)
- Naoya Sakamoto (ORCID: https://orcid.org/0000-0003-0061-059X)
- Goki Suda (ORCID: https://orcid.org/0000-0003-0098-9106)
- Shinichiro Minami (ORCID: https://orcid.org/0009-0008-8735-291X)
- Keisuke Kakisaka (ORCID: https://orcid.org/0000-0001-9627-138X)
- Masaru Baba (ORCID: https://orcid.org/0000-0002-4142-3267)
- Masashi Ninomiya (ORCID: https://orcid.org/0000-0002-6154-8075)
- Kei Sawara (ORCID: https://orcid.org/0000-0003-4608-277X)
- Takuya Sho (ORCID: https://orcid.org/0000-0001-7943-3842)
- Mio Tsuruoka (ORCID: https://orcid.org/0009-0009-7693-3505)
- Tomohiro Katsumi (ORCID: https://orcid.org/0000-0001-5670-7505)
- Yoshiyuki Ueno (ORCID: https://orcid.org/0000-0001-5623-4250)
- Hidekatsu Kuroda (ORCID: https://orcid.org/0000-0002-1471-1087)
- Chikara Iino (ORCID: https://orcid.org/0000-0001-6844-4415)
- Kei Endo (ORCID: https://orcid.org/0000-0002-9698-2779)
- Takayuki Matsumoto (ORCID: https://orcid.org/0000-0001-9786-3854)
- Yoshiya Yamamoto
- Takayoshi Oikawa (ORCID: https://orcid.org/0000-0002-1100-6980)
- Takashi Meguro
- Go Igarashi
- Keita Maki
- Yudai Fujiwara
- Kenta Yoshida
- Masashi Fujita
- Satoshi Sato
- Takuya Watanabe
- Yuichi Yoshida
- Tokio Sasaki
Publication Details
- Journal
- Liver Cancer
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1159/lic/admag030
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00